9th Annual Update in Peritoneal Malignancies

General considerations

8.30am - 8.45am : Quality control of HIPEC-does methodology matter

8.45am - 9.15am : PSOGI-ESGO-ISSPP consensus on CRS- Introduction,results, Hidden regions

9.15am - 9.27am : The HIPEC vs NIPEC trial - Background, Design, Challenges and Update

9.27am - 9.40am : Takeaways from the 2022 PSOGI consensus on HIPEC regimens

9.40am - 10.00am : Discussion (all speakers and chairpersons)

10.00am - 10.30am : COFFEE BREAK

10.30am - 10.40am : Translational research in PSM

10.40am - 10.50am : Imaging for PSM- what the surgeon should know (with case illustrations)

10.50am - 11.00am : Complications of CRS and their prevention (with case illustrations)

11.00am - 11.10am : FAPI vs Conventional imaging in Ovarian cancers

11.10am - 11.20am : Overcoming the learning curve for cytoreductive surgery and HIPEC

11.20am - 11.30am : New concepts in intraperitoneal chemotherapy

11.30am - 11.40am : ICG guided surgery for peritoneal metastasis

11.40am - 11.50am : Discussion

11.50am - 12.30pm : Complications/ Imaging challenges (Case discussion)

12.30pm - 1.30pm : LUNCH BREAK

Advanced ovarian cancer

1.30pm - 1.45pm : Prevention of tumour cell entrapment in locoregional control of Gynaecological cancers

1.45pm - 2.00pm : Update of surgical consideration for ovarian cancer in era of GOG trials : Integration CRS and HIPEC with systemic therapy : what? how ? and when?

2.00pm - 2.15pm : Optimizing patient selection for primary and interval cytoreductive surgery

2.15pm - 2.30pm : KELIM in ovarian cancer

2.30pm - 3.00pm : Pro-con session: Bevacizumab in ovarian cancer

3.00pm - 3.15pm : The journey to becoming an ESGO centre of excellence

3.15pm - 3.45pm : COFFEE BREAK

3.45pm - 4.00pm : Recurrent ovarian cancer-indications and patient selection for cytoreductive surgery

4.00pm - 4.15pm : Optimizing the use of PARPi in the management of ovarian cancer in Indian Patients

4.15pm - 4.45pm : Pro-con session: HIPEC after secondary CRS for platinum sensitive recurrence

4.45pm - 5.00pm : PIPAC in the management of ovarian cancer

5.00pm - 5.15pm : Low grade serous ovarian cancer - Role of CRS/HIPEC

5.15pm - 5.30pm : Total mesenteric peritonectomy-technique and patient selection

5.30pm - 6.15pm : Clinical Case Discussion (Advanced/recurrent ovarian cancer)

Colorectal peritoneal metastases (HALL A)

8.30am - 8.45am : Colorectal cancer peritoneal metastases- what should be in the guidelines

8.45am - 9.00am : Timing of systemic chemotherapy in patients with colorectal PM and predictors of response

9.00am - 9.15am : Incorporating radiotherapy in the treatment of rectal peritoneal metastases

9.15am - 9.45am : Pro and Con session: Minimally-invasive cytoreductive surgery

9.45am - 10.00am : The road ahead with HIPEC in Colorectal cancer

10.00am - 10.30am : COFFEE BREAK

10.45am - 11.00am : Role of PIPAC in the management of colorectal peritoneal metastases

11.00am - 11.15am : Management of dMMR colorectal PM

11.15am - 11.30am : ISPSM and Kolgo prospective RCT trials in PSM

11.30AM - 11.45am : Mucin in the peritoneum - what does it indicate?

11.45am - 12.30pm : Clinical case discussion - Management of Ovaries, High PCI, adverse histology,molecular profile

12.30pm - 1.30pm : LUNCH BREAK

Gastric cancer and peritoneal metastases

1.30pm - 1.45am : PIPAC for gastric cancers

1.45pm - 2.00pm : Prophylactic HIPEC and HIPEC for cytology positive gastric cancer

2.00pm - 2.15pm : Poorly cohesive and Signet Ring Cancers

2.15pm - 2.45pm : Post DRAGAON era - should NIPS be incorporated into routine care?

2.45pm - 3.30pm : Clinical case discussion: Gastric cancer/ rare disease

3.30pm - 4.00pm : COFFEE BREAK

Peritoneal mesothelioma and other rare peritoneal malignancies

4.00pm - 4.15m : Current management of Peritoneal Mesothelioma

4.15pm - 4.30pm : Multi-society consensus on peritoneal malignancies- methodology and key messages

4.30pm - 4.45pm : Uncommon indications for CRS/HIPEC

Best of Asia

4.45pm - 5.00pm : Update of ISPSM registry audit:what we learn from Indian data?

5.00pm - 5.15pm : State of art PSM center in China-what can the world learn from it

5.15pm - 5.30pm : Tumour infiltrating lymphocytes and their relevance in ovarian cancer

5.30am - 5.45am : NAC- the technology and the initial experience

5.45pm - 6.00pm : Nepal Experience with CRS + HIPEC

6.00pm - 6.15pm : Malaysian experience with CRS+ HIPEC

6.15pm - 6.30pm : Sri Lanka Experience with CRS HIPEC

Perioperative management of patients undergoing CRS and HIPEC (HALL B)

9.00am - 9.15am : Setting up a HIPEC program, learning curve, perioperative management

9.15am - 9.30am : AIIMS experience

9.30am - 9.45am : Data from Max/ PSM Program

9.45am - 10.00am : Training in PSM - how much is enough?

10.00am - 10.15am : Challenges with CRS and HIPEC as compared to other oncological surgeries

10.15am - 10.45am : COFFEE BREAK

10.45am - 11.00am : Anaesthesia for CRS HIPEC-A multivariate approach

11.00am - 11.15am : CRS and HIPEC under regional anesthesia

11.15am - 11.30am : Fluid dynamics:The intraoperative balance

11.45am - 12.00am : Strategies to improve periop management - MVR protocol

12.00am - 12.15pm : Management of coagulation profile

12.15pm - 12.30pm : Managing the bowel - anastomoses / stoma

12.30pm - 12.45pm : Rare complications of CRS and HIPEC

12.45pm - 1.00pm : Rare anesthesia complications

1.00pm - 2.00pm : LUNCH BREAK

2.00pm - 2.15pm : Perioperative pain - Strategies for success

2.15pm - 2.30pm : Prehabilitation: A fitting prelude

HIPEC Program & Perioperative Management

2.30pm - 2.45pm : Industry video 1. Baxter- Starling monitor 2. Edward’s- Flowtrac

2.45pm - 3.00pm : Post operative fluid management in ICU following CRS HIPEC

3.00pm - 3.15pm : ERAS essentials for CRS and HIPEC

3.15pm - 3.30pm : INDEPSO-ISPSM ERAS guidelines- what should be applied in clinical practice

3.30pm - 3.45pm : Group discussion-- Indian guidelines for perioperative management

Pseudomyxoma peritonei (HALL A)

8.30am - 8.45am : Primary appendiceal tumours and PMP – Pathology

8.45am - 9.00am : Clinical trials and new treatments for PMP

9.00am - 9.15am : Management of the ovaries during cytoreductive surgery for pseduomyxoma peritonei

9.15am - 9.35am : Organoids in the management of peritoneal metastases- the NCI Milan experience

9.35am - 9.45am : Systemic therapy for pseudomyxoma peritonei

9.45am - 10.30am : Clincial case discussion:controversies in PMP

10.30am - 11.00am : COFFEE BREAK

11.00am - 11.20am : Multi-viceral transplant session: Introduction and Transcape study

11.20am - 11.30am : Case illustrations and experience at MGM

11.30am - 11.40am : Home TPN

11.40am - 12.10pm : Paul Sugarbaker Oration - Management of gastric peritoneal metastases

12.15pm - 12.45pm : The Rolling Stone Awards

12.45pm - 1.30pm : LUNCH BREAK

Invited original studies

1.30pm - 1.40pm I : Management of incidental appendiceal tumours- Indian conssus

1.40pm - 1.50pm : Peritoneal mesothelioma-Indian experience

1.50pm - 2.00pm : TMH gastric cancer experience-any surprises?

2.00pm - 2.10pm : Colorectal peritoneal and lung metastases

2.10pm - 2.20pm : Signet ring cell colorectal cancer:outcomes of the Colo SRC study

2.20pm - 2.30pm : Morphology of peritoneal lesions

2.40pm - 2.50pm : Staging laparoscopy and FAPI PET for HPB malignancies-experience from a north Indian centre

2.50pm - 3.00pm : Thoracic cytoreduction in ovarian cancer- a bicentre experience

3.00pm - 3.10pm : Organoid in the management of peritoneal metastases- the TMH experience

3.15pm - 3.45pm : COFFEE BREAK

Top abstracts and videos

3.45pm - 4.10pm : Top 3 Oral Abstracts (8min each)

4.15pm - 4.25pm : Top Video

4.30pm : Group photo and closure

Pathology workshop (HALL B)

9.00 am : Pathological classification of appendiceal tumors and PMP

9.15 am : TILS guidelines and Challenges

9.30 am : Protocol for grossing and assessment of CRS specimens

9.45 am : Pathological PCI (pathologists perspective)

10.00 am : Pathological PCI (surgeons’s perspective)- with data from the PRECINCT study

10.15 am : Discussion

10.30 am : Coffee Break

11.00 am : Diagnostic challenges in peritoneal mesothelioma

11.15 am : Bohm score - how to assess it and utility

11.30 am : Rare diseases- slide show and expert comments

12.00 pm : Rare epithelial ovarian tumor- diagnostic dilemmas and current standards

12.15 pm : Response to systemic chemotherapy in non-ovarian malignancies

12.30 pm : PRGS (Indian Data)score in PIPAC- what is the use?

12.45 pm : Lunch Break

1.30 pm : Presentation of best abstracts (8 mins each)

2.00 pm : TILS working group meeting